Differentiated Thyroid Cancer Clinical Trial
Official title:
Diagnosing Thyroid Cancer Using a Blood Test
Thyroid cancer is a relatively rare disease but its incidence is increasing in many countries.. Early and accurate diagnosis leading to earlier treatment and intervention is recognised as a major factor in determining a good outcomes. This study will investigate new ways of diagnosing thyroid cancer from blood samples using proteomic and genetic markers. The study will take samples from patients with differentiated thyroid cancer and measure relative quantities of 1000s of proteins within the blood. These measures will be explored to see if, when used in combination they can accurately diagnose thyroid cancer. If successful this technique could be extended to routine screening and could replace more invasive tests currently used. Participants will be required to supply a small sample of blood, answer questions on their medical history and also consent for their medical records to be examined. A lifestyle questionnaire will also be supplied to each participant. In the case where a diagnosis is predicted for a condition the participant was not aware of the medical team will discuss the best interests of the patient with their GP and if required refer them to a suitable specialist. The study will run for 24 months and will routinely process around 15 and 20 participants with a history of thyroid cancer per month. All patient details will be kept confidential and only non identifiable information will leave the clinic. The work will be published and if successful will be validated on another site, commercialised and made available for routine clinical use.
This project will utilize two powerful technologies for diagnosing endocrine diseases:
proteomics and genetic (RNA and DNA) markers. Proteomics is a relatively new, rapidly
expanding and exciting area of biomedical research (Robin et al, 2009, Frolich et al, 2009).
Posttranslational modifications of proteins are critical for function. Modified proteins may
be markers of cancer phenotypes and therefore be useful tumor markers (Narimatsu et al,
2010). Proteomic research in thyroid cancer is in its infancy (Krause et al, 2009). The
available studies on thyroid cancer have utilised tissue rather than serum samples,
nonetheless the results are encouraging (Brown et al, 2006, Wang et al, 2006, Netea-Maier et
al, 2008, Krause et al, 2007, Moretz et al, 2008).
Genomic markers of thyroid cancer have been described and are increasingly being used on
biopsy material for accurate diagnosis. Among the described markers point mutations (BRAF
V600E, NRAS codon 61, HRAS codon 61), gene rearrangements (RET / PTC1, RET / PTC3, PAX8 /
PPARgamma) and other polymorphisms have been found to be useful (Nikiforova and Nikiforov,
2009, Ohori et al, 2010). There is good evidence that in recurrent thyroid cancer small
numbers of thyroid cancer cells can be detected in peripheral blood, in sufficient quantities
to detect thyroid-specific mRNA by RT PCR (Karavitaki et al, 2005, Barbosa et al, 2008, Milas
et al, 2009). Most of these studies have focused on the detection of thyroglobulin mRNA with
moderate success. A significant difficulty with this approach is that detection of
thyroglobulin mRNA in peripheral blood cannot distinguish between the presence of normal
thyroid tissue or thyroid cancer.
The project is a collaborative venture between Newcastle Biomedicine, the NHS, and
Biosignatures Ltd (a North-East based proteomics diagnostics company). Biosignatures has
invested a great deal of research in optimizing sample handling and sample analysis, thus
giving rise to plasma proteomic protocols that are stable and suitable for large comparative
studies (Elliott et al, Jackson et al, 2010, Bramwell et al, 2007). The data generated from
plasma 2D gel electrophoresis and mass spectroscopy is analysed by proprietary "supervised
learning" technology. The system is given multiple examples of group classes (disease cases)
and from this derives a signature pattern ('proteomic fingerprint') that allows the classes
to be discriminated. This signature will then be validated against a novel patient dataset to
ensure robust disease status discrimination. The combination of this research and technology
can produce blood derived signatures of disease in an applied clinical setting (Cash and
Argo, 2009, Borthwick et al, 2009).
Thyroid cancer affects 2000 new patients in the UK per annum (Cancer Research UK). Once the
initial treatment of thyroid cancer is completed (thyroidectomy followed by radioiodine
ablation), monitoring is essential to detect residual disease or recurrence. Recurrence rates
in thyroid cancer are as high as 30% (Mazzaferri and Kloos, 2001) and can declare themselves
decades after initial treatment, so that patients have to be monitored regularly for life.
Monitoring for disease recurrence consists of iodine scans, an ultrasound scan of the neck
6-8 months after initial treatment, and 6-12 monthly blood tests thereafter for the serum
marker thyroglobulin. Thyroglobulin is a valuable marker in many people with thyroid cancer
(Spencer and Fatemi, 2006). Unfortunately in approximately 30% of patients antibody
interference with the assay renders this test unreliable (Spencer and Fatemi, 2006). In such
cases patients are subjected to repeated scans, though a negative scan has a far less
predictive value than a negative thyroglobulin blood test when the analyte can be measured
reliably. We have selected thyroid cancer as the primary topic of study for proof of concept
for the following reasons:
- Current diagnostics technology (measurement of serum thyroglobulin) suffers from
interference of measurement of the analyte in 30% of cases, rendering this tumour marker
entirely unreliable when such antibodies are present. Attempts using conventional
biochemical analytical technology to overcome this problem over the past 3 decades have
failed. Thus a proteomics/genomics approach has only to perform with a better than 70%
specificity to provide a superior diagnostic test.
- The potential cost savings to the NHS by the development of such a diagnostic test (by
avoidance of expensive scans) will be considerable.
- Exposure of patients to radiation from repeated scans will be reduced with obvious
safety benefits.
- The study is non-interventional, will induce no additional discomfort, and is expected
to have no impact on the care received by participants at this stage.
- Extrapolation of such technology to the evaluation of thyroid nodules (present
clinically in 5% of the adult population) and even screening of the population for
thyroid malignancy, would have profoundly beneficial preventative and public health
consequences.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02870569 -
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
|
Phase 2 | |
Completed |
NCT01876784 -
Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
Completed |
NCT04971473 -
Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone Withdrawal
|
Phase 3 | |
Recruiting |
NCT04964284 -
Efficacy and Safety Study of rhTSH for Adjuvant Radioiodine Ablation Therapy in Patients With Differentiated Thyroid Cancer
|
Phase 3 | |
Recruiting |
NCT05078853 -
Thyroglobulin Point of Care Assay for Rapid Detection of Metastatic Differentiated Thyroid Carcinoma
|
||
Active, not recruiting |
NCT03690388 -
A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
|
Phase 3 | |
Recruiting |
NCT02638077 -
Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China
|
N/A | |
Recruiting |
NCT01700699 -
Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors
|
N/A | |
Completed |
NCT03176485 -
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
|
N/A | |
Recruiting |
NCT04563780 -
The Prognostic Value of Post Thyroidectomy 99mTCpertechnetate Thyroid Scan in Patient With Differentiated Thyroid Cancer
|
||
Completed |
NCT03191643 -
PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer
|
N/A | |
Completed |
NCT02278198 -
Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123
|
Phase 1 | |
Active, not recruiting |
NCT04447183 -
The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
|
Phase 2 | |
Active, not recruiting |
NCT01263951 -
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
|
Phase 2 | |
Recruiting |
NCT04940052 -
Study of Efficacy and Safety of Dabrafenib Plus Trametinib in Previously Treated Patients With Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E Mutation-positive Differentiated Thyroid Cancer
|
Phase 3 | |
Recruiting |
NCT04880798 -
Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer
|
N/A | |
Recruiting |
NCT05789667 -
Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer
|
||
Recruiting |
NCT05660954 -
Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.
|
Phase 2 | |
Completed |
NCT00295763 -
A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.
|
Phase 3 |